<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02010359</url>
  </required_header>
  <id_info>
    <org_study_id>1K23DK095913-01A1</org_study_id>
    <secondary_id>1K23DK095913-01A1</secondary_id>
    <nct_id>NCT02010359</nct_id>
  </id_info>
  <brief_title>Fish Oils and Adipose Inflammation Reduction</brief_title>
  <acronym>FAIR</acronym>
  <official_title>Omega-3 PUFA Suppress Adipochemokines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical trial designed to assess whether fish oil treatments are effective&#xD;
      in the prevention of obesity-related fat tissue (adipose) inflammation. Specifically it&#xD;
      addresses the hypothesis that fish oils treatments will reduce signaling by chemokine&#xD;
      pathways (fractalkine and MCP-1) important in adipose tissue for the recruitment and&#xD;
      activation of certain white blood cells (macrophages). The study is a double-blind&#xD;
      placebo-controlled trial of the fish oil Lovaza from GlaxoSmithKline (omega-3-acid ethyl&#xD;
      esters; a combination of ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid&#xD;
      (DHA)) in obese non-diabetic adults, to determine if Lovaza decreases markers of inflammation&#xD;
      and macrophage activation in adipose and blood and understand the mechanism by which fish&#xD;
      oils affect inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a parallel arm, double blind, placebo-controlled trial to understand&#xD;
      the anti-inflammatory and metabolic effects of marine derived omega-3 fatty acids (EPA + DHA)&#xD;
      on obesity-related inflammation and chemokine signaling in humans. Obese (BMI&gt;30 kg/m2) but&#xD;
      non-diabetic young males and females (n~44; 25 to 50 years of age) taking no omega-3 fatty&#xD;
      acid (EPA + DHA) supplements and consuming a low fish diet (defined as usual intake of high&#xD;
      omega-3 fish (tuna and other non-fried fish) &lt; 3 to 4 servings per month) will be included. A&#xD;
      low habitual fish intake is important to control EPA + DHA intake during the supplement&#xD;
      period (see exclusion criteria below). Subjects also will be required to maintain their&#xD;
      current fish intake throughout the treatment period.&#xD;
&#xD;
      There will be two treatment groups; (1) placebo and (2) omega-3 fatty acids 4 grams/day. The&#xD;
      trial will be randomized, double blind, placebo-controlled, with parallel treatment groups;&#xD;
      treatment with omega-3 fatty acids 8 weeks. We will enroll participants until at least 22&#xD;
      subjects per study-arm complete all study visits (i.e., at least 44 participants).&#xD;
&#xD;
      Prescription Lovaza (omega-3-acid ethyl esters) from GlaxoSmithKline at 4 grams day (2 1-gram&#xD;
      capsules twice daily, with food) will be used. We expect this dose to be safe because it is a&#xD;
      dose that is recommended, and routinely used, for management of moderate or worse&#xD;
      hypertriglyceridemia (levels &gt; 400 mg/dL). We will use matching placebo capsules so that all&#xD;
      participants are taking 2 capsules twice daily - with food as recommended in clinical&#xD;
      practice.&#xD;
&#xD;
      The study duration was chosen in order to provide adequate time for potential&#xD;
      anti-inflammatory effects of treatments without requiring maximum lipid modifying effects&#xD;
      while also reducing the potential for drop-out and loss to follow up that is associated with&#xD;
      longer study durations.&#xD;
&#xD;
      Participants will be recruited from the Preventive Cardiology Research databases, comprised&#xD;
      of healthy subjects who have participated in previous research studies and who have asked to&#xD;
      be contacted for future studies. Potential participants will also be recruited via local&#xD;
      IRB-approved flyers, internet, and newspaper advertisements (see flyer and advertisement&#xD;
      attached) targeting the Delaware Valley region.&#xD;
&#xD;
      STUDY PROCEDURES&#xD;
&#xD;
      Informed Consent Before study initiation, the clinical protocol, the Informed Consent Form&#xD;
      (ICF), and any advertisements for subject recruitment will be submitted for review and&#xD;
      approval to the Institutional Review Board (IRB). The investigator, or his designated&#xD;
      research staff, will obtain written informed consent from each subject enrolled in the study,&#xD;
      in accordance with the U.S. Food and Drug Administration (FDA) regulations 21 CFR parts&#xD;
      50.20-50.27. It is the responsibility of the investigator to ensure that informed consent is&#xD;
      obtained from the subject or his/her guardian or legal representative before any activity or&#xD;
      treatment is undertaken which is not part of routine care.&#xD;
&#xD;
      Safety Assessments Safety will be evaluated by the incidence, severity, and relationship to&#xD;
      treatment agent of adverse events.&#xD;
&#xD;
      Monitoring for Adverse Events: Details of all AEs that occur after the first dose of study&#xD;
      drug will be collected as indicated in Section 12. Any illness or injury that occurs before&#xD;
      the first dose of a study drug will be recorded under Medical History and evaluated to&#xD;
      determine if the occurrence affects the patient's eligibility to participate in the study.&#xD;
      Subjects will be asked the following standard questions by the designated clinical evaluator:&#xD;
      At clinic check-ins:&#xD;
&#xD;
        1. &quot;Have you had any medical problems since your last visit?&quot;&#xD;
&#xD;
        2. &quot;Have any medical problems present at your last visit changed, i.e., stopped, worsened,&#xD;
           or improved?&quot;&#xD;
&#xD;
        3. &quot;Have you taken any medicines, other than study drug, since your last visit?&quot; Any&#xD;
           spontaneous AE information provided by the patient will be recorded. NOTE: An AE may be&#xD;
           a new disease(s), any untoward event(s), or an exacerbation of a pre existing condition.&#xD;
           See Section 12.0 for complete details.&#xD;
&#xD;
      Adipose biopsy: Approximately 500-1000 mg of subcutaneous adipose tissue will be biopsied&#xD;
      from the gluteal region, processed, weighed and frozen until analyzed. Adipose tissue will be&#xD;
      obtained through a small (~5mm) incision under local anesthesia (2% Lidocaine without&#xD;
      epinephrine), as has been previously described13-15. A portion (200 mg) of the samples will&#xD;
      be flash frozen and analyzed for gene expression and protein assays. Another portion (500-800&#xD;
      mg) will be placed in sterile media and undergo digestion with collagenase, filtration, and&#xD;
      centrifugation for separation of the stromal vascular fraction (SVF). SVF cells will be&#xD;
      stained with antibodies for flow cytometer analysis. Finally, remaining tissue will be fixed&#xD;
      in paraffin for immunohistochemistry.&#xD;
&#xD;
      6.5 Subgingival analysis&#xD;
&#xD;
      Saliva samples will be collected using the OMNIgene DISCOVER (OM-505) kit (DNA Genotek), an&#xD;
      all-in-one kit which collects and stabilizes both microbial DNA and RNA in saliva. Samples&#xD;
      will be stored at -80C prior to extraction. Nucleic acids will be extracted using the QIAGEN&#xD;
      QIAamp MinElute Virus Spin Kit (Qiagen). Subgingival plaque samples will be obtained from 3&#xD;
      oral cavity regions in each subject (2 samples per region) using a soft-bristled microbrush&#xD;
      (DenTek). Specimens will be collected from the same anatomical location in all subjects. DNA&#xD;
      will be isolated using the PSP Spin Stool DNA kit (Invitec). DNA samples will be amplified&#xD;
      using V1-V2 region primers targeting bacterial 16S genes and sequenced using IlluminaHiSeq or&#xD;
      454 Pyrosequencing technology.&#xD;
&#xD;
      Specific Study Procedures (by visit)&#xD;
&#xD;
      Screening (Visit 1) Potential participants will be screened first by a telephone or e-mail&#xD;
      interview with the research coordinator (see Appendix B for email interview form; for&#xD;
      telephone interviews this information will be verbally exchanged). Participants who meet&#xD;
      initial study requirements will be invited for a screening visit (visit 1) at the CTRC. Prior&#xD;
      to this visit, participants will receive a detailed health questionnaire (see Appendix C)&#xD;
      that has been used in numerous previous studies that addresses questions regarding past&#xD;
      medical history, current use of medications and dietary supplements, exercise and social&#xD;
      habits. In addition, participants will be asked about fish consumption in order to ensure&#xD;
      recruitment of subjects with lower EPA + DHA intake during the study period. Participants&#xD;
      will be asked to complete these questionnaires at home and bring the completed forms with&#xD;
      them to their screening visit. During the screening visit, they will meet with research staff&#xD;
      to review and sign an IRB-approved consent form. Research staff will review the health&#xD;
      questionnaire with the participant as well as measure weight, height, waist and hip&#xD;
      circumference, sitting blood pressure and heart rate. A brief physical exam will be performed&#xD;
      as well as an electrocardiogram (ECG). In addition, participants will have blood drawn (after&#xD;
      a 12 hour fast) for evaluating fasting lipids, glucose, serum chemistries and liver function&#xD;
      and a complete blood count. Female participants will also be asked to provide a urine sample&#xD;
      for a pregnancy test. These laboratory parameters are included to assure the participant&#xD;
      meets eligibility criteria and that he/she is generally in good health. Once all clinical&#xD;
      data has been reviewed, study personnel will contact each study volunteer to let them know if&#xD;
      they are eligible.&#xD;
&#xD;
      Randomization visit (Visit 2) One to four weeks after the screening Visit 1, eligible&#xD;
      participants will return to the CTRC after a 12 hour fast for a 2 hour visit. Participants&#xD;
      will be asked to brush their teeth after their last meal the day before the visit, or at the&#xD;
      start of the 12-hour fasting period, and to refrain from additional brushing or use of&#xD;
      mouthwash until after the study visit. Participants will meet with a research nurse /&#xD;
      coordinator who will assess any change in medical history and medication use, as well as&#xD;
      review any adverse events. Blood pressure, heart rate, height and weight will be measured,&#xD;
      blood and urine will be collected for pre-randomization baseline efficacy measures and a&#xD;
      urine pregnancy test performed for all females. The simple fish consumption questionnaire&#xD;
      will be administered to assess any changes to the level of omega-3 intake in the diet.&#xD;
&#xD;
      They will also be asked to record all food and beverages consumed on dietary records on 3&#xD;
      days prior to the visit, as well as completing a digestive health questionnaire and diet&#xD;
      history questionnaire. All nutrient data collected from 3-day dietary records will be&#xD;
      analyzed by Food Processor 8.1 (06/03, Escha). Participants will be asked to complete these&#xD;
      questionnaires at home and bring the completed forms with them to their study visit. If a&#xD;
      subject is unable to print out or complete the forms at home, they will be completed at the&#xD;
      visit.&#xD;
&#xD;
      Saliva and subgingival plaque samples will be taken for assessment of oral microbiome. Saliva&#xD;
      samples will be collected using a standardized kit. Under the supervision of study personnel,&#xD;
      subjects will be given the kit, which consists of a funnel attached to a tube, and instructed&#xD;
      to spit into the funnel until the amount of liquid reaches a fill line located on the outside&#xD;
      of the attached tube. Once the proper amount has been collected, the lid of the funnel will&#xD;
      be closed and the funnel removed from the tube. The tube is then capped and shaken for about&#xD;
      10 seconds. Subgingival plaque samples will be collected by swabbing several regions of the&#xD;
      buccal mucosa using microbrushes. A separate brush will be used for each swab and two samples&#xD;
      will be collected from each region.&#xD;
&#xD;
      In order to establish effects of treatments on adipose inflammatory parameters, we will&#xD;
      obtain gluteal region subcutaneous adipose tissue biopsies under local anesthesia (2%&#xD;
      Lidocaine). A detailed description of the adipose collection procedures is given in Section&#xD;
      6.4. Participants will then be randomized to drug or placebo group. Supplies of study drug&#xD;
      will be provided to last 8 weeks (4 pills/day of either Lovaza or placebo).&#xD;
&#xD;
      Participants will be provided verbal and written instruction to take the study drugs as&#xD;
      follows; 2 fish oil/placebo with food in the morning, 2 fish oil/placebo with food in the&#xD;
      evening. A pill diary will be given to all subjects.&#xD;
&#xD;
      Telephone / E-mail Follow up (Visit 3) Participants will be contacted by telephone or e-mail&#xD;
      approximately four weeks (visit 3) post-randomization to review medication compliance and&#xD;
      pill diary, adverse events and any changes in fish consumption. Participants with &lt;80%&#xD;
      apparent adherence to study medication will be counseled to increase compliance so that their&#xD;
      adherence at 8 weeks will be ≥80%.&#xD;
&#xD;
      Completion Visit (Visit 4) Participants will come to the CTRC after a 12 hour fast.&#xD;
      Participants will meet with a study coordinator who will assess changes to the medical&#xD;
      history and medication use. They will also be asked to record all food and beverages consumed&#xD;
      on dietary records on 3 days prior to the visit. Any adverse events will be recorded, pill&#xD;
      diary reviewed, and study medications will be counted (pill count) Weight and height will be&#xD;
      recorded and BMI calculated. ECG will be performed. Blood will be drawn for post-drug&#xD;
      screening of liver functions and chemistries as well as for all outcome-related measures&#xD;
      (lipids, insulin/glucose, inflammatory markers). Urine for efficacy measures will also be&#xD;
      collected. Urine pregnancy test will be performed in all females. Saliva and subgingival&#xD;
      plaque samples will be taken to assess for any change in oral microbiome by the treatment. An&#xD;
      adipose biopsy will be performed as above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Fractalkine Levels</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Quantification of fractalkine levels in plasma at baseline and after 8 weeks of Lovaza or placebo will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Interleukin 6 (IL-6)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Quantification of plasma IL-6 at baseline and after 8 weeks of Lovaza/placebo will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Monocyte Chemotactic Protein-1 (MCP-1)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Quantification of plasma MCP-1 at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Tumor Necrosis Factor Alpha (TNFalpha)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Quantification of plasma TNFalpha at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Ratio of Circulating Monocyte Subpopulations</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Ratio of inflammatory CX3CR1lowCCR2+ to less inflammatory CX3CR1hiCCR2- monocytes by flow cytometry at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mRNA Expression of Fractalkine in Adipose</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>relative mRNA quantification (fold change) from baseline to 8 weeks of Lovaza/placebo will be compared in each subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mRNA Levels of MCP-1 in Adipose</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mRNA Levels of IL6 in Adipose</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mRNA Levels of TNFalpha in Adipose</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ratio of Adipose Tissue Macrophage Subpopulation</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Ratio of M1 to M2 macrophages in adipose by flow cytometry at baseline and after 8 weeks Lovaza/placebo will be compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lovaza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>Lovaza 4 grams per day</description>
    <arm_group_label>Lovaza</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and non-pregnant/lactating women between the ages of 25 and 50.&#xD;
&#xD;
          2. Body Mass Index (BMI) ≥30 kg/m2&#xD;
&#xD;
          3. Participants who are able to give written informed consent and willing to comply with&#xD;
             all study-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes Mellitus (glucose fasting &gt;126, or random &gt;200, Hemoglobin A1C&gt;6.5 %, or use&#xD;
             of any anti-diabetic agent)&#xD;
&#xD;
          2. Self-reported fish or shellfish allergy&#xD;
&#xD;
          3. Planned usage of any prescription or non-prescription medication (other than&#xD;
             contraceptive pills or devices) during the study period.&#xD;
&#xD;
          4. Recent (within 6 months) use of fish oil supplements or self- reported dietary intake&#xD;
             of &gt;3 servings of fish/month&#xD;
&#xD;
          5. Blood pressure &gt;140/90&#xD;
&#xD;
          6. Recent (within 6 months) use of statins, niacin, or fenofibrates&#xD;
&#xD;
          7. Current or planned pregnancy/lactation. Pre-menopausal women unwilling to prevent&#xD;
             pregnancy by use of the following approved contraceptive strategies: diaphragm,&#xD;
             cervical cap, condom with spermicide, surgical sterility, birth control pills,&#xD;
             Depo-Provera injection, Intra-uterine device, progestin implant, or abstinence.&#xD;
&#xD;
          8. History of liver disease or abnormal liver function tests (aspartate aminotransferase,&#xD;
             Alanine transaminase, Alkaline Phosphatase, gamma-glutamyl transpeptidase &gt; 1.5x Upper&#xD;
             Limit normal; bilirubin &gt; 2x upper limit normal) at Screening Visit&#xD;
&#xD;
          9. Men who are unwilling to limit alcohol consumption to &lt; 14 alcoholic drinks per week&#xD;
             or &lt; 4 alcoholic drinks per occasion while participating in the study&#xD;
&#xD;
         10. Women who are unwilling to limit alcohol consumption to &lt; 7 alcoholic drinks per week&#xD;
             or &lt; 3 alcoholic drinks per occasion while participating in the study.&#xD;
&#xD;
         11. Hemoglobin less than 11.0 g/dL&#xD;
&#xD;
         12. Any reported arrhythmia, usage of anti-arrhythmic therapy, or abnormal screening&#xD;
             electrocardiogram&#xD;
&#xD;
         13. Known bleeding disorder or coagulopathy&#xD;
&#xD;
         14. Any major active rheumatologic, pulmonary, hematologic or dermatologic disease or&#xD;
             inflammatory condition or minor active infection&#xD;
&#xD;
         15. Self-reported history of HIV positive&#xD;
&#xD;
         16. Patients who have undergone any organ transplant&#xD;
&#xD;
         17. Individuals who currently use tobacco products or have done so in the previous 30 days&#xD;
&#xD;
         18. Treatment with aspirin, non steroidal anti-inflammatories, COX-2 inhibitors, steroids&#xD;
             or any immunomodulatory therapy 2 weeks prior to the Screening Visit&#xD;
&#xD;
         19. Participants who are unwilling to eliminate omega-3 fatty acid (EPA + DHA) supplements&#xD;
             and/or fortified food, or have their usual intake of high omega-3 fish (tuna and other&#xD;
             non-fried fish) be &gt; 3 to 4 servings per month as assessed by a simple screening&#xD;
             questionnaire&#xD;
&#xD;
         20. Recent (within 6 months) treatment with coumarin-type anticoagulants&#xD;
&#xD;
         21. Positive urine pregnancy test result.&#xD;
&#xD;
         22. Self-reported history of injected recreational drug use.&#xD;
&#xD;
         23. Any medical condition or abnormal laboratory value that is judged clinically&#xD;
             significant by an investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachana Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>October 31, 2018</results_first_submitted>
  <results_first_submitted_qc>January 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02010359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lovaza</title>
          <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lovaza</title>
          <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="9.4"/>
                    <measurement group_id="B2" value="37.4" spread="8.4"/>
                    <measurement group_id="B3" value="36.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="5.5"/>
                    <measurement group_id="B2" value="35.9" spread="6.1"/>
                    <measurement group_id="B3" value="36" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fasting glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.4" spread="11.6"/>
                    <measurement group_id="B2" value="87.8" spread="10.2"/>
                    <measurement group_id="B3" value="87.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fasting triglyceride</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138.8" spread="107.6"/>
                    <measurement group_id="B2" value="92.9" spread="35.1"/>
                    <measurement group_id="B3" value="116.8" spread="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Fractalkine Levels</title>
        <description>Quantification of fractalkine levels in plasma at baseline and after 8 weeks of Lovaza or placebo will be compared.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Fractalkine Levels</title>
          <description>Quantification of fractalkine levels in plasma at baseline and after 8 weeks of Lovaza or placebo will be compared.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.1"/>
                    <measurement group_id="O2" value="0.46" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.1"/>
                    <measurement group_id="O2" value="0.45" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Interleukin 6 (IL-6)</title>
        <description>Quantification of plasma IL-6 at baseline and after 8 weeks of Lovaza/placebo will be compared.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Interleukin 6 (IL-6)</title>
          <description>Quantification of plasma IL-6 at baseline and after 8 weeks of Lovaza/placebo will be compared.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.6"/>
                    <measurement group_id="O2" value="1.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.5"/>
                    <measurement group_id="O2" value="2.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Monocyte Chemotactic Protein-1 (MCP-1)</title>
        <description>Quantification of plasma MCP-1 at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Monocyte Chemotactic Protein-1 (MCP-1)</title>
          <description>Quantification of plasma MCP-1 at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="15.8"/>
                    <measurement group_id="O2" value="139" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" spread="29.1"/>
                    <measurement group_id="O2" value="123" spread="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Tumor Necrosis Factor Alpha (TNFalpha)</title>
        <description>Quantification of plasma TNFalpha at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Tumor Necrosis Factor Alpha (TNFalpha)</title>
          <description>Quantification of plasma TNFalpha at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.51"/>
                    <measurement group_id="O2" value="0.74" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.21"/>
                    <measurement group_id="O2" value="0.74" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Ratio of Circulating Monocyte Subpopulations</title>
        <description>Ratio of inflammatory CX3CR1lowCCR2+ to less inflammatory CX3CR1hiCCR2- monocytes by flow cytometry at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Ratio of Circulating Monocyte Subpopulations</title>
          <description>Ratio of inflammatory CX3CR1lowCCR2+ to less inflammatory CX3CR1hiCCR2- monocytes by flow cytometry at baseline and after 8 weeks of Lovaza/placebo will be compared</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.11"/>
                    <measurement group_id="O2" value="0.35" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.1"/>
                    <measurement group_id="O2" value="0.31" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in mRNA Expression of Fractalkine in Adipose</title>
        <description>relative mRNA quantification (fold change) from baseline to 8 weeks of Lovaza/placebo will be compared in each subject</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>There were 4 participants that did not have sufficient adipose tissue in the biopsy for RT-PCR</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in mRNA Expression of Fractalkine in Adipose</title>
          <description>relative mRNA quantification (fold change) from baseline to 8 weeks of Lovaza/placebo will be compared in each subject</description>
          <population>There were 4 participants that did not have sufficient adipose tissue in the biopsy for RT-PCR</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.1"/>
                    <measurement group_id="O2" value="1.06" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in mRNA Levels of MCP-1 in Adipose</title>
        <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>4 participants did not have sufficient adipose tissue in biopsy for RT-PCR</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in mRNA Levels of MCP-1 in Adipose</title>
          <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
          <population>4 participants did not have sufficient adipose tissue in biopsy for RT-PCR</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.05" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in mRNA Levels of IL6 in Adipose</title>
        <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>4 participants did not have sufficient adipose tissue from biopsy for RT PCR</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in mRNA Levels of IL6 in Adipose</title>
          <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
          <population>4 participants did not have sufficient adipose tissue from biopsy for RT PCR</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.1"/>
                    <measurement group_id="O2" value="1.08" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in mRNA Levels of TNFalpha in Adipose</title>
        <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>4 subjects did not have sufficient adipose tissue from biopsy for RT-PCR</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in mRNA Levels of TNFalpha in Adipose</title>
          <description>relative mRNA quantification (fold change) from baseline to 8 weeks of treatment in Lovaza vs. placebo groups, as measured by RT-PCR</description>
          <population>4 subjects did not have sufficient adipose tissue from biopsy for RT-PCR</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.8"/>
                    <measurement group_id="O2" value="2.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ratio of Adipose Tissue Macrophage Subpopulation</title>
        <description>Ratio of M1 to M2 macrophages in adipose by flow cytometry at baseline and after 8 weeks Lovaza/placebo will be compared</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>4 participants did not sufficient adipose tissue from biopsy for flow cytometry analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ratio of Adipose Tissue Macrophage Subpopulation</title>
          <description>Ratio of M1 to M2 macrophages in adipose by flow cytometry at baseline and after 8 weeks Lovaza/placebo will be compared</description>
          <population>4 participants did not sufficient adipose tissue from biopsy for flow cytometry analysis</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.3"/>
                    <measurement group_id="O2" value="0.64" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.52"/>
                    <measurement group_id="O2" value="0.42" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lovaza</title>
          <description>Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks&#xD;
Lovaza</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>An inactive Placebo (2 pills twice daily) will be given for 8 weeks&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skiing accident</sub_title>
                <description>Knee injury during skiing during study participation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rachana Shah</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>215-590-3390</phone>
      <email>shahr@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

